NEW YORK (GenomeWeb News) – Joel McComb is leaving his post as senior VP and GM of Illumina's Life Sciences business to become COO at Synthetic Genomics. McComb will depart Illumina and take on the new position at SGI, where he will report to founder and CEO J. Craig Venter, effective March 1.
Before his time at Illumina, McComb was at General Electric, where he was president of Healthcare Life Sciences-Discovery Systems, and he served as president of GE Healthcare, Interventional Medicine. He also previously served as president and CEO of Innovadyne Technologies, a liquid handling technology firm.
McComb's departure agreement from Illumina entitles him to a severance payment of nearly $260,000.
SDIX said this week that Orchid Cellmark CEO and President Thomas Bologna has joined its board of directors. Thomas Wurzer, managing director of investments at Connecticut Innovations, also has joined the SDIX board. SDIX offers a range of immuno-solution capabilities for the life sciences, pharmaceutical, biotech, diagnostics, and food safety markets.
Thermo Fisher Scientific paid out an $825,000 bonus in 2009 to CEO and President Marc Casper, and the firm said that Casper's 2010 salary will be $1 million, with a target bonus this year of 115 percent of salary, according to a filing this week with the US Securities and Exchange Commission.
Thermo Fisher Senior VP and CFO Peter Wilver received a bonus of $450,000, and will receive a 2010 salary of $616,000 with a target bonus at 75 percent of salary. Senior VP Alan Malus earned a $460,000 bonus for 2009, and in 2010 will receive $570,000 with a target bonus of 75 percent. Senior VP, General Counsel, and Secretary Seth Hoogasian earned a 2009 bonus of $313,000 and in 2010 will be paid a salary of $495,000 and will have a target bonus set at 65 percent.
Paul Graham, CEO of Graham Capital Partners, has joined the board of directors at Health Discovery Corporation. Graham replaces outgoing board member Michael Hanbury, who resigned to take an executive position with Spectrum Laboratory Network in Greensboro, NC. Graham Capital Partners provides investment banking and advisory services to companies with revenue between $10 million and $100 million.
Professor Harald Mischak has been named chair of proteomics at the University of Glasgow. In the position, which is funded by the Medical Research Council, Mischak will lead proteomics research within the British Heart Foundation Glasgow Cardiovascular Research Centre at the University.
Mischak is director of Mosaiques Diagnostics and Therapeutics, a firm focused on developing protein and peptide biomarker-based early detection technologies for cardiovascular, renal, and urogenital diseases.
Atossa Genetics has tapped Edward Sauter, associate dean for research at the University of North Dakota School of Medicine and Health, to serve on its scientific advisory board. Atossa Genetics is developing novel cellular and molecular diagnostic risk assessment products for breast cancer. Atossa President and CEO Steven Quay said in a statement that Sauter is "an accomplished surgeon and breast cancer researcher," and that he "brings a broad expertise in translational research."
Diagnostics For All this week announced that Una Ryan is taking over as its president and CEO, replacing James Barber. Ryan has more than 20 years of executive experience in biotechnology and pharmaceuticals, DFA said in a statement. Most recently, she was CEO of Waltham Technologies. Before that she was president and CEO of Avant Immunotherapeutics.
Barber had served as CEO of DFA on a part-time, unpaid basis since the company's founding.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.